The Masimo technology is designed to provide non-invasive and continuous measurement of multiple blood constituents, fluid responsiveness and other physiological parameters. That helps caregivers identify conditions such as low levels of blood oxygen, hemoglobin, and/or perfusion, as well as elevated levels of carbon monoxide and methemoglobin in the blood, abnormal pulse rates, and fluid responsiveness, according to a press release.
"Through our focused Monitoring Solutions division, GE Healthcare is committed to optimally collecting information from the patient’s body, and transforming it into meaningful intelligence for caregivers. Masimo’s suite of noninvasive and continuous Rainbow SET measurements will further enhance the point-of-care clinical intelligence benefits already offered in GE Healthcare’s patient monitors," Matthias Weber, the division’s general manager, said in prepared remarks.
"GE Healthcare’s patient monitoring lines have a long history of innovative clinical measurements and system solutions that enhance patient care decisions. We are excited to announce this expansion of our partnership with GE Healthcare and are proud to work with them to incorporate rainbow SET measurements in their monitoring solutions to continue this tradition for the benefit of customers and the patients they serve," added Rick Fishel, president of Masimo’s worldwide OEM business & corporate development.
The surgical device maker said it expects full-year dividend to be about 60 cents per share, "equivalent to a dividend yield of approximately 2.0% based on the closing price of ConMed’s stock as of Feb. 29, 2012." Future dividends will be issued at the board’s discretion. Read more
Align Technology’s R&D head cashes in
Dana Cambra, the vice president of research & development for Align Technology (NSDQ:ALGN), cashed in $1.5 million worth of stock, according to a regulatory filing. Cambra sold 58,095 shares for an average of $25.90 apiece. ALGN shares were trading at $25.88 as of about 12:30 p.m. today. Read more
GPOs: Premier inks deals with Bard, GE, Philips
Premier healthcare alliance inked new invasive cardiology equipment supply deals with C.R. Bard (NYSE:BCR), GE’s (NYSE:GE) Medical Systems Information Technologies division and Philips Healthcare (NYSE:PHG). Read more
- Hologic retires $500M in long-term notes
- Neotherix reels in $330k
- Intact Vascular raises $2.5M
- Iagnosis drums up $1M
- Life Sciences Greenhouse drops $250k on Micro Interventional Devices
- AtriCure (NSDQ:ATRC): Barrington Research reiterates "outperform" rating, $17 price target.
- Cerner (NSDQ:CERN): Sterne Agee initiates coverage with "buy" rating, $85 price target; Deutsche Bank increases price target to $85 from $76, maintains "buy" rating.
- Integra LifeSciences (NSDQ:IART): Barrington Research reiterates "outperform" rating, $50 price target.
- LeMaitre Vascular (NSDQ:LMAT): TheStreet Ratings downgrades from "buy" to "hold;" Canaccord Genuity lowers price target to $7.50, maintains "buy" rating.
- NxStage Medical (NSDQ:NXTM): Leerink Swann reiterates "outperform" rating, $25 price target; Feltl & Co. lowers rating to "hold," cuts its price target to $22.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.